Bio-Rad Laboratories (NYSE:BIO - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, February 13th. Analysts expect the company to announce earnings of $2.86 per share and revenue of $679.75 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.
Bio-Rad Laboratories Stock Down 1.1 %
Shares of NYSE BIO traded down $3.72 during mid-day trading on Friday, reaching $341.69. 231,287 shares of the company's stock were exchanged, compared to its average volume of 151,421. Bio-Rad Laboratories has a twelve month low of $262.12 and a twelve month high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $9.57 billion, a price-to-earnings ratio of -12.50 and a beta of 0.90. The business has a fifty day simple moving average of $341.16 and a 200 day simple moving average of $336.87.
Wall Street Analysts Forecast Growth
Several analysts have commented on the stock. Citigroup raised their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $394.20.
Read Our Latest Stock Report on BIO
About Bio-Rad Laboratories
(
Get Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Further Reading
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
